Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Osmotica Pharmaceuticals Plc (OSMT)  
$0.00 0.00 (9,900.00%) as of 4:30 Thu 5/2


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 63,780,000
Market Cap: 6.38(K)
Last Volume: 0 Avg Vol: 0
52 Week Range: $0.000001 - $0.94
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   RVL Pharmaceuticals is a holding company. Through its subsidiaries, Co. is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patients in the ocular medicine and medical aesthetics therapeutic areas. Co.'s portfolio includes RVL-1201, or Upneeq, (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy or low-lying eyelids in adults. Co. has expanded its commercialization activities among ophthalmology, optometry and oculoplastic specialties. Co. makes Upneeq available through RVL Pharmacy, Inc., its wholly-owned pharmacy.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 25,000,000
Total Buy Value $0 $0 $0 $38,750,000
Total People Bought 0 0 0 5
Total Buy Transactions 0 0 0 5
Total Shares Sold 0 0 35,088,392 35,088,392
Total Sell Value $0 $0 $1,602,356 $1,602,356
Total People Sold 0 0 2 2
Total Sell Transactions 0 0 6 6
End Date 2024-02-01 2023-10-31 2023-05-02 2022-05-02

   
Records found: 76
  Page 3 of 4  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Venkataraman Sriram Director   –       •       •   2020-11-20 4 D $0.00 $0 I/I (4,936,926) 0     -
   Orbit Co-Invest Iii Llc 10% Owner   –       –       •   2020-11-20 4 D $0.00 $0 I/I (4,936,926) 0     -
   Cowan Gregory L Director   –       •      –    2020-05-21 4 D $4.60 $51,115 D/D (11,112) 79,650     -
   Weiss Fred G Director   –       •      –    2020-05-21 4 D $4.60 $81,779 D/D (17,778) 86,873     -
   Markison Brian A Chief Executive Officer   •       •      –    2020-05-20 4 A $0.00 $0 D/D 249,787 2,126,020     -
   Cowan Gregory L Director   –       •      –    2020-05-20 4 A $0.00 $0 D/D 38,716 90,762     -
   Weiss Fred G Director   –       •      –    2020-05-20 4 A $0.00 $0 D/D 38,716 104,651     -
   Klein Christopher General Counsel and Secretary   •       –      –    2020-05-18 4 A $0.00 $0 D/D 71,550 227,434     -
   Einhorn Andrew J. Chief Financial Officer   •       –      –    2020-05-18 4 A $0.00 $0 D/D 71,550 167,215     -
   Schaub James EVP and COO   •       –      –    2020-05-18 4 A $0.00 $0 D/D 73,253 328,408     -
   Devries Tina Marie EVP, Research & Development   •       –      –    2020-05-18 4 A $0.00 $0 D/D 71,550 167,259     -
   Schaub James EVP and COO   •       –      –    2020-01-28 4 D $7.00 $64,379 D/D (9,197) 255,155     -
   Cowan Gregory L Director   –       •      –    2020-01-28 4 D $7.00 $38,535 D/D (5,505) 52,046     -
   Klein Christopher General Counsel & Secretary   •       –      –    2020-01-28 4 D $7.00 $64,036 D/D (9,148) 155,884     -
   Weiss Fred G Director   –       •      –    2020-01-28 4 D $7.00 $38,535 D/D (5,505) 65,935     -
   Einhorn Andrew J. Chief Financial Officer   •       –      –    2020-01-28 4 D $7.00 $64,288 D/D (9,184) 95,665     -
   Devries Tina Marie EVP, Research & Development   •       –      –    2020-01-28 4 D $7.00 $63,980 D/D (9,140) 95,709     -
   Weiss Fred G Director   –       •      –    2019-06-18 4 A $0.00 $0 D/D 37,037 71,440     -
   Cowan Gregory L Director   –       •      –    2019-06-18 4 A $0.00 $0 D/D 23,148 57,551     -
   Markison Brian A Chief Executive Officer   •       •      –    2019-02-25 4 A $0.00 $0 D/D 387,991 1,876,233     -
   Cowan Gregory L Director   –       •      –    2019-01-24 4 A $0.00 $0 D/D 34,403 34,403     -
   Schaub James EVP and COO   •       –      –    2019-01-24 4 A $0.00 $0 D/D 104,849 264,352     -
   Einhorn Andrew J. Chief Financial Officer   •       –      –    2019-01-24 4 A $0.00 $0 D/D 104,849 104,849     -
   Devries Tina Marie EVP, Research & Development   •       –      –    2019-01-24 4 A $0.00 $0 D/D 104,849 104,849     -
   Klein Christopher General Counsel and Secretary   •       –      –    2019-01-24 4 A $0.00 $0 D/D 104,849 165,032     -

  76 Records found
  1  2  3  4   
  Page 3 of 4
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed